no such thing as T4 lah !! market got all type of margin agreement, T1 to to T12 also can be arranged. If a share want to goreng up your T4 also will go up !!! Moreover how to classify T3 T4,your T3,T4 could be another guy T1 T2 or syndicate T6 T7 !!! to me hovid is not a very good share,its a trading share only, those traders in kenaga,RHB,Cimb alway play up 0.5 to 1 sen and unload all to market !!! hovid is a typical trading share, just buy red and sell green wont be wrong punya !!
Author: kiasutrader | Publish date: Fri, 10 Jan 16:14
Hovid sees great potential in the coming years. It recently launched generic versions of drugs which went off patent 2011. An estimated USD15bn in medicines have gone off patent in 2013, boosting its potential new products pipeline. Plans are already in place to raise production capacity by 30% in 2014. We value the stock at 42 sen, pegged to 17x CY14F fully diluted EPS – an 18% upside.
We hosted a corporate luncheon with Hovid for our clients in Dec 2013. Management was represented by CFO and executive director Mr Andrew Goh. Given the current trend of patent protection expiry for major “innovator drugs”, management was upbeat on Hovid’s prospects as a generic drug manufacturer. We concur with this view. The company is now ramping up capacity to capitalise on this trend. Tasty takeaways from the luncheon. Among the notable takeaways from the luncheon were the fact that Hovid: i) recently launched generic versions of two drugs whose patent protection recently expired – these medicines generated a combined USD9.7bn annually in global sales before their patents ended, and ii) is working on a further six generic versions of major drugs in 2014. Based on estimates, there at least 17 drugs – worth USD15bn in total global sales – whose patents expired last year. 3-year (FY13-16) net profit CAGR of 21.9%. Hovid plans to launch 10-12 new products annually going forward. To support its ambitions, the company is: i) expanding capacity at its tablet and capsule plant this year with a planned initial “30% increase”, ii) setting up its own bioequivalence test centre for new generic drugs, and iii) building a new central warehouse to better manage the increase in inventory. MYR0.42 FV, 18% upside. We value Hovid at 17x CY14F fully diluted EPS, a discount to global peers average of 18x 2014 earnings. That said, while there is a substantial warrant base, we do not think conversions are likely at this juncture. Pre-dilution, Hovid’s share price would be 61 sen at 17x P/E. We like the company for its: i) 21.9% 3-year earnings CAGR, ii) strong exposure to the export market – ie wellpositioned to benefit from further USD/MYR appreciation, iii) net cash position, and iv) decent 15% ROE. This stock is Not Rated.
Hovid has ROE of between 12.5% to 13.1% from 2012 to 2013 which is better than current FD rate of 3%, beneficiary of weak ringgit as Hovid imports most of its raw materials and derives half of its sales from the export markets denominated in USD....
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Alex Leow Sze Shen
5,009 posts
Posted by Alex Leow Sze Shen > 2014-01-10 11:15 | Report Abuse
Profit taking in place, today is T+4